Galera Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Galera Therapeutics, Inc. (GRTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are GRTX insiders buying or selling?
In the last 12 months, Galera Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.4K) — net selling of $1.4K. Since November 2019, Trabud has recorded 36 Form 4 filings for GRTX: 19 buys ($31.0M) and 17 sells ($20.2M).
Source: SEC EDGAR Form 4
What stands out
- No Galera Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 1 reported open-market sale totaled $1.4K.
Key Statistics (November 2019 – Nov 24, 2025)
Total Form 4 filings
36
SEC EDGAR
Insider filers
15
Insider buys (19)
$31.0M
Insider sells (17)
$20.2M
Insider sentiment
Net buyingNet insider flow of $10.8M in net buying since November 2019, and $1.4K in net selling over the last 12 months.
Recent GRTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | Mel Sorensen | President and CEO | Sale | 70.0K | $0.02 | $1.4K | SEC ↗ |
| Jan 2, 2025 | CHANG NANCY T | Director, 10% Owner | Purchase | 7.6M | $0.07 | $500.0K | SEC ↗ |
| Aug 20, 2024 | Mel Sorensen | President and CEO | Sale | 67.0K | $0.07 | $4.8K | SEC ↗ |
| May 1, 2024 | Schneid Yair | 10% Owner | Purchase | 2.8M | $0.21 | $590.4K | SEC ↗ |
| Feb 26, 2024 | Schneid Yair | 10% Owner | Purchase | 932.4K | $0.18 | $166.4K | SEC ↗ |
| Mar 20, 2023 | Mark Bachleda | Chief Commercial Officer | Purchase | 11.0K | $2.25 | $24.7K | SEC ↗ |
| Mar 14, 2023 | Mel Sorensen | President and CEO | Purchase | 100.0K | $1.68 | $168.1K | SEC ↗ |
| Mar 14, 2023 | Chris Degnan | Chief Financial Officer | Purchase | 10.0K | $1.96 | $19.6K | SEC ↗ |
| Dec 20, 2021 | Linda West | Director | Purchase | 20.0K | $2.74 | $54.8K | SEC ↗ |
| Sep 3, 2021 | HOLMLUND JON T | Chief Medical Officer | Sale | 47.8K | $8.47 | $404.5K | SEC ↗ |
| Jun 17, 2021 | Linda West | Director | Purchase | 10.0K | $9.13 | $91.3K | SEC ↗ |
| Jun 5, 2021 | Linda West | Director | Purchase | 10.0K | $8.65 | $86.5K | SEC ↗ |
| Jun 3, 2021 | Lawrence M Alleva | Director | Purchase | 4.0K | $8.59 | $34.7K | SEC ↗ |
| Jun 2, 2021 | Linda West | Director | Purchase | 20.0K | $8.64 | $172.8K | SEC ↗ |
| Feb 19, 2021 | Novo Holdings A/S | 10% Owner | Sale | 500.0K | $10.58 | $5.3M | SEC ↗ |
| Nov 17, 2020 | Lawrence M Alleva | Director | Purchase | 2.3K | $10.22 | $23.8K | SEC ↗ |
| Nov 17, 2020 | Joel F. Sussman | Chief Accounting Officer | Sale | 20.0K | $10.19 | $203.8K | SEC ↗ |
| Oct 28, 2020 | HOLMLUND JON T | Chief Medical Officer | Sale | 2.2K | $15.00 | $33.7K | SEC ↗ |
| Oct 19, 2020 | Novo Holdings A/S | 10% Owner | Sale | 450.0K | $11.00 | $5.0M | SEC ↗ |
| Oct 7, 2020 | HOLMLUND JON T | Chief Medical Officer | Sale | 10.6K | $12.00 | $127.6K | SEC ↗ |
| Jun 22, 2020 | Novartis Bioventures Ltd | Other | Sale | 1.0M | $8.25 | $8.3M | SEC ↗ |
| Jun 17, 2020 | Novartis Bioventures Ltd | 10% Owner | Sale | 19.4K | $9.21 | $178.6K | SEC ↗ |
| Jun 12, 2020 | Novartis Bioventures Ltd | 10% Owner | Sale | 17.2K | $9.33 | $160.8K | SEC ↗ |
| Jun 10, 2020 | Novartis Bioventures Ltd | 10% Owner | Sale | 21.3K | $9.57 | $203.9K | SEC ↗ |
| Jun 4, 2020 | Novartis Bioventures Ltd | 10% Owner | Sale | 15.0K | $9.68 | $144.9K | SEC ↗ |
Showing the 25 most recent of 36 Form 4 filings for Galera Therapeutics, Inc..
Most active GRTX insiders
- HOLMLUND JON T7 filings
- Novartis Bioventures Ltd6 filings
- Linda West4 filings
- Lawrence M Alleva3 filings
- Mel Sorensen3 filings
Ask anything about GRTX insider activity
Use Trabud's AI agent to query Galera Therapeutics, Inc.'s Form 4 history in plain English — "Show me GRTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentGRTX insider trading FAQ
Are Galera Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Galera Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.4K) — net selling of $1.4K. Since November 2019, Trabud has recorded 36 Form 4 filings for GRTX: 19 buys ($31.0M) and 17 sells ($20.2M). Over the full record that is net buying of $10.8M.
How many insiders trade GRTX stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Galera Therapeutics, Inc.. The most recent filing was accepted on Nov 24, 2025.
Where does Trabud get GRTX insider trading data?
All GRTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.